መነሻ › የጉበት ካንሰር (ሄፓቶሴሉላር ካርሲኖማ) › ሚዙሪ
በሚዙሪ ለየጉበት ካንሰር (ሄፓቶሴሉላር ካርሲኖማ) የሚደረጉ ክሊኒካዊ ጥናቶች
ለየጉበት ካንሰር (ሄፓቶሴሉላር ካርሲኖማ) የሚደረጉ 14 ጥናቶች በሚዙሪ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በሚዙሪ ውስጥ ያሉ ከተሞች
Official study text (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ45 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, St Louis
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Siteman Cancer Center - St. Peters, City of Saint Peters
- Siteman Cancer Center - West County, Creve Coeur
- Siteman Cancer Center - North County, Florissant
- እና 6 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07227012A Study Evaluating a New Radiation Treatment Workflow (NGDS)
- Siteman Cancer Center Washington University, St Louis
ተሳታዮችን በመፈለግ ላይ
እድሜ 21 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT07824583Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, St Louis
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Washington University School of Medicine, St Louis
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
12 Months – 30 Years · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Washington University School of Medicine, St Louis
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT07166406First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, St Louis
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ኦገስ 2026 · NCT06795022IDOV-Immune for Advanced Solid Tumors
- Washington University School of Medicine, St Louis
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦገስ 2026 · NCT06910657A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Mosaic Life Care at Saint Joseph - Medical Center, Saint Joseph
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 8 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ27 ጁላይ 2026 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO, St Louis
ተሳታዮችን በመፈለግ ላይ
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT05486572A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Washington University in St. Louis, St Louis
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ27 ኤፕሪ 2026 · NCT05440708SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Kansas City
- Massive Bio SYNERGY-AI site, St Louis
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦክቶ 2025 · NCT03452774ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።